Psychostimulant-induced behavior as an animal model of obsessive-compulsive disorder: An ethological approach to the form of compulsive rituals

CNS Spectrums

Volumn 10, Issue 3, 2005, Pages 191-202

  Eilam, David ^a   Szechtman, Henry ^b,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b MCMASTER UNIVERSITY   (Canada)

^c Ontario Mental Health Foundation   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CLOMIPRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; FLUOXETINE; PSYCHOSTIMULANT AGENT; QUINPIROLE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; COMPULSION; DOPAMINERGIC SYSTEM; LOCOMOTION; NEUROBIOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; REVIEW;

EID: 16844379173     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285290001004X     Document Type: Review

References (103)

1. Abramson LY, Seligman MEP. Modeling psychopathology in the laboratory: History and rationale. In: Maser JD, Seligman MEP, eds. Psychopathology: Experimental Models. San Franscisco, Calif: Freeman; 1977:1-26.
2. McKinney WT Jr, Bunney WE Jr. Animal model of depression. I. Review of evidence: implications for research. Arch Gen Psychiatry. 1969;21:240-248.
3. Willner P. The validity of animal models of depression. Psychopharmacology (Berl). 1984;83:1-16.
4. Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev. 1992;16:525-534.
5. Geyer MA, Markou A. Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:787-798.
6. McKinney WT. Models of Mental Disorders: A New Comparative Psychiatry. New York, NY: Plenum Medical Book Co; 1988.
7. Randrup A, Munkvad I. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia. 1967;11:300-310.
8. Schiorring E. Psychopathology induced by "speed drugs". Pharmacol Biochem Behav. 1981;1(suppl 1):109-122.
9. Schiorring E. An open field study of stereotyped locomotor activity in amphetamine-treated rats. Psychopharmacology (Berl). 1979;66:281-287.
10. Schiorring E. Amphetamine induced selective stimulation of certain behaviour items with concurrent inhibition of others in an open-field test with rats. Behaviour. 1971;39:1-17.
11. Ellinwood EH Jr, Kilbey MM. Amphetamine stereotypy: the influence of environmental factors and prepotent behavioral patterns on its topography and development. Biol Psychiatry. 1975;10:3-16.
12. Kety SS. Mental illness and the sciences of brain and behavior. Nat Med. 1999;5:1113-1116.
13. Matthysse S. Animal models in psychiatric research. Prog Brain Res. 1986;65:259-270.
14. Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry. 1976;133:197-202.
15. Snyder SH. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am J Psychiatry. 1973;130:61-67.
16. Snyder SH, Aghajanian GK, Matthysse S. Prospects for research on schizophrenia. V. Pharmacological observations, Drug-induced psychoses. Neurosci Res Program Bull. 1972;10:430-445.
17. Rasmussen S, Eisen JL. Phenomenology of OCD: clinical subtypes, heterogeneity and coexistence. In: Zohar J, Insel T, Rasmussen S, eds. The Psychobiology of Obsessive-Compulsive Disorder. New York, NY: Springer Publishing Company; 1991:13-43.
18. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry. 1990;51(suppl):36-43.
19. Stein DJ. Obsessive-compulsive disorder. Lancet. 2002;360:397-405.
20. Reed GF. Obsessional Experience and Compulsive Behaviour: A Cognitive-Structural Approach. Orlando, Fl: Academic Press, Inc.; 1985.
21. Rachman S, Shafran R. Cognitive and behavioral features of obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachman S, Richter MA, eds. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. New York, NY: Guiford Press; 1998:51-78.
22. Henderson JG Jr, Pollard CA. Three types of obsessive compulsive disorder in a community sample. J Clin Psychol 1988;44:747-752.
23. Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry. 1992;53:(suppl):4-10.
24. Insel TR. Obsessive-compulsive disorder: a neuroethological perspective. Psychopharmacoi Bull 1988;24:365-369.
25. Rapoport JL. The biology of obsessions and compulsions. Sci Am. 1989;260:82-89.
26. Lorenz K. On Aggression, 1st ed. New York, NY: Harcourt, Brace & World; 1966.
27. Jenike MA, Baer L, Minichiello WE. Obsessive-Compulsive Disorders: Theory and Management. 2nd ed. Chicago, Ill: Year Book Medical Publishers, Inc; 1990.
28. Szechtman H, Sulis W, Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behatv Neurosci. 1998;112:1475-1485.
29. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
30. Rapoport JL. The Boy Who Couldn't Stop Washing: The Experience and Treatment of Obsessive-Compulsive Disorder. 1st ed. New York, NY: E.P. Dutton; 1989.
31. Marks IM. Fears, Phobias, and Rituals: Panic, Anxiety, and Their Disorders. New York, NY: Oxford University Press; 1987.
32. Serruya D, Eilam D. Stereotypies, compulsion and normal behavior in the context of motor routines in the rock hyrax (Procavia Capensis). Psychobiology. 1996;24:235-246.
33. Szechtman H, Talangbayan H, Canaran G, Dai H, Eilam D. Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism. Psychopharmocology (Berl). 1994;115:95-104.
34. Ben Pazi A, Szechtman H, Eilam D. The morphogenesis of motor rituals in rats treated chronically with the dopamine agonist quinpirole. Behav Neurosci. 2002;115:1301-1317.
35. Szechtman H, Eckert MJ, Tse WS, et al. Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): form and control. BMC Neurosci. 2001;2:4.
36. Immelmann K, Beer C. A Dictionary of Ethology. Cambridge, Mass: Harvard University Press; 1989.
37. Szechtman H, Eilam D. Psychiatric models. In: Whishav: IQ, Kolb B, eds. The Behavior of the Laboratory Rat: A Handbook With Tests. New York, NY: Oxford University Press; 2005:462-474.
38. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48:730-738.
39. Leonard HL, Swedo SE, Lenane MC et al. A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry. 1992;50:429-439.
40. Tizabi Y, Louis VA, Taylor CT, Waxman D, Culver KE, Szechtman H. Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder. Biol Psychiatry. 2002;51:164-171.
41. Brown RW, Thompson KD, Thompson KN, et al. Adulthood nicotine treatment alleviates behavioural impairments in rats neonatally treated with quinpirole: possible roles of acetylcholine function and neurotrophic factor expression. Eur J Neurosci. 2004;19:1634-1642.
42. Brus R, Kostrzewa RM, Nowak P, Perry KW, Kostrzewa JP. Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats. Neurotox Res. 2003;5:329-338.
43. Tizabi Y, Copeland RL Jr, Brus R, Kostnewa RM. Niconne blocks quinpirole-induced behavior in rats: psychiatric implications. Psychopharmacology (Berl). 1999;145:433-441.
44. Seeman P. Receptor Tables, Vol. 2. Drug Dissociation Constants for Neuroreceptors and Transporters. Toronto, Canada: SZ Research; 1993.
45. Eilam D, Canaran G, Szechtman H. Compulsive and rigid locomotion produced by chronic treatment with the D2 agonist quinpirole. Soc Neurosci Abstr. 1989;15:1157.
46. Eilam D, Szechtman H. Towards an animal model of obsessive-compulsive disorder (OCD): sensitization to dopamine agonist quinpirole. Soc Neurosci Abstr. 1995;21:192.
47. Einat H, Szechtman H. Perseveration without hyperlocomotion in a spontaneous alternation task in rats sensitized to the dopamine agonist quinpirole. Physiol Behav. 1995;57:55-59.
48. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302-308.
49. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794-801.
50. Miguel EC, Shavitt RG, Ferrao YA, Brotto SA, Diniz JB. How to treat OCD in patients with Tourette syndrome. J Psychosom Res. 2003;55:49-57.
51. Ramasubbu R. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent. Arch Gen Psychiatry. 2002;59:472-473.
52. Khulfar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci. 2001;26:55-59.
53. Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65;1040-1048.
54. Frisch A, Michaelovsky E, Rockah R et al. Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur Neuropsychopharmacol. 2000;10:205-209.
55. Hemmings SM, Kinnear CJ, Niehaus DJ, et al. Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2003;13:93-98.
56. Kim CH, Koo MS, Cheon KA, Ryu YH, Lee JD, Lee HS. Dopamine transporter density of basal ganglia assessed with [(123)1J1PT SPET in obsessive-compulsive disorder. Eur J Nucl Med Mol Imaging. 2003;30:1637-1643.
57. Millet B, Chabane N, Delorme R, et al. Association between the dopamine receptor D4 (DRD4) gene and obsessive-compulsive disorder. Am J Med Genet. 2003;116:55-59.
58. Billett EA, Richter MA, Sam F, et al. Investigation of dopamine system genes in obsessive-compulsive disorder. Psychiatr Genet. 1998;8:163-169.
59. Denys D, van der WN, Janssen J, de Geus F, Westenberg HG. Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry. 2004;55:1041-1045.
60. Karayiorgou M, Altemus M, Galke BL, et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci US A. 1997;94:4572-4575.
61. Karayiorgou M, Sobin C, Blundell ML, et al. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol Psychiatry. 1999;45:1178-1189.
62. Zohar J, Chopra M, Sasson Y, Amiaz R, Amital D. Obsessive compulsive disorder: serotonin and beyond. World J Biol Psychiatry. 2000;1:92-100.
63. Szechtman H, Culver K, Eilam D. Role of dopamine systems in obsessive-compulsive disorder (OCD): implications from a novel psychostimulant-induced animal model. Pol J Pharmacol. 1999;51:55-61.
64. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 1986;396:157-198.
65. Szechtman H, Dai H, Mustafa S, Einat H, Sullivan RM. Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. Pharmacol Biochem Behav. 1994;48:921-928.
66. Einat H, Einat D, Allan M, Talangbayan H, Tsafnat T, Szechtman H. Associational and nonassociational mechanisms in locomotor sensitization to the dopamine agonist quinpirole. Psychopharmacology (Berl). 1996;127:95-101.
67. Szechtman H, Talangbayan H, Eilam D. Environmental and behavioral components of sensitization induced by the dopamine agonist quinpirole. Behav Pharmacol. 1993;4:405-410.
68. Szumlinski KK, Allan M, Talangbayan H, Tracey A, Szechtman H. Locomotor sensitization to quinpirole: environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmocology (Berl). 1997;134:193-200.
69. Baxter LRJ, Schwartz JM, Bergman KS, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49:681-689.
70. Baxter LRJ. Neuroimaging studies of obsessive compulsive disorder. Psychiatr Clin North Am. 1992;15:871-884.
71. Benkelfat C, Nordahl TE, Semple WE, King AC, Murphy DL, Cohen RM. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. Arch Gen Psychiatry 1990;47:840-848.
72. Swedo SE, Pietrini P, Leonard HL, et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Arch Gen Psychiatry. 1992;49:690-694.
73. Kim JJ, Lee MC, Kim J, et al. Grey matter abnormalities in obsessive-compulsive disorder: statistical parametric mapping of segmented magnetic resonance images. Br J Psychiatry. 2001;179:330-334.
74. Jenike MA, Baer L, Ballantine T, et al. Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients. Arch Gen Psychiatry. 1991;48:548-555.
75. Kettl PA, Marks IM. Neurological factors in obsessive compulsive disorder. Two case reports and a review of the literature. Br J Psychiatry. 1986;149:315-319.
76. Chiocca EA, Martuza RL. Neurosurgical therapy of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Theory and Management. Chicago, Ill: Year Book Medical Publishers Inc; 1990;283-294.
77. Baer L, Rauch SL, Ballantine HT, et al. Cingulotomy for intractable obsessive-compulsive disorder-prospective long-term follow-up of 18 patients. Arch Gen Psychiatry. 1995;52:384-392.
78. Dougherty DD, Baer L, Cosgrove GR, et al. Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry. 2002;159:269-275.
79. Saxena S, Bota RG, Brody AL. Brain-behavior relationships in obsessive-compulsive disorder. Semin Clin Neuropsychiatry. 2001;6:82-101.
80. Modell JG, Mountz JM, Curtis GC, Greden JE Neurophysiologic dysfunction in basal ganglia/limbic striatai and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1989;1:27-36.
81. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23:563-586.
82. Insel TR. Toward a neuroanatomy of obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49:739-744.
83. Szechtman H, Woody E. Obsessive-compulsive disorder as a disturbance of security motivation. Psychol Rev. 2004;111:111-127.
84. Yadin E, Friedman E, Bridget WH. Spontaneous alternation behavior: an animal model for obsessive- compulsive disorder? Pharmacol Biochem Behav. 1991;40:311-315.
85. Fernandez-Guasti A, Ulloa RE, Nicolini H. Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder. Psychopharmacology (Berl). 2003;166:195-201.
86. Ulloa RE, Nicolini H, Fernandez-Guasti A. Age differences in an animal model of obsessive-compulsive disorder: participation of dopamine: dopamine in an animal model of OCD. Pharmacol Biochem Behav. 2004;78:661-666.
87. Woods A, Smith C, Szewczak M, Dunn RW, Cornfeldr M, Corbett R. Selective serotonin re-uptake inhibitors decrease schedule- induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology (Berl). 1993;112:195-198.
88. Roehr J, Woods A, Corbett R, Kongsamut S. Changes in paroxetine binding in the cerebral cortex of polydipsic rats. Eur J Pharmacol 1995;278:75-78.
89. Alternas M, Glowa JR, Murphy DL. Attenuation of food-restriction-induced running by chronic fluoxetine treatment. Psychopharmacol Bull. 1993;29:397-400.
90. Altemus M, Glowa JR, Galliven E, Leong YM, Murphy DL. Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol Biochem Behav. 1996;53:123-131.
91. Abe M, Nakai H, Tabata R, Saito K, Egawa M. Effect of 5-[3-[((2S)-1,4-benzo-dioxan-2-ylmethyl)amino]propoxy]-1,3-benzodioxofe HCl (MKC-242), a novel 5-HT1A-receptor agonist, on aggressive behavior and marble burying behavior in mice. Jpn J Pharmacol. 1998;76:297-304.
92. Ichimaru Y, Egawa T, Sawa A. 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol. 1995;68:65-70.
93. Millan MJ, Girardon S, Mullot J, Brocco M, Dekeyne A. Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists. Neuropharmacology. 2002;42:677-684.
94. Takeuchi H, Yatsugi S, Yamaguchi T. Effect of YM992, a novel antidepressant with selective Serotonin re-uptake inhibitory and 5-HT(2A) receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model. Jpn J Pharmacol 2002;90:197-200.
95. Yamada K, Wada E, Yamano M, et al. Decreased marble burying behavior in female mice lacking neuromedin-B receptor (NMB-R) implies the involvement of NMB/ NMB-R in 5-HT neuron function. Brain Res. 2002;942:71-78.
96. Archer T, Fredriksson A, Lewander T, Soderberg U. Marble burying and spontaneous motor activity in mice: interactions over days and the effect of diazepam. Scand J Psychol. 1987;28:242-249.
97. Broekkamp CL, Rijk HW, Joly-Gelouin D, Lloyd KL. Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol. 1986;126:223-229.
98. Gyertyan I. Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying. Behav Pharmacol. 1995;6:24-31.
99. Njung'e K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav. 1991;38:63-67.
100. Joel D, Avisar A. Excessive lever pressing following post-training signal attenuation in rats: a possible animal model of obsessive compulsive disorder? Behav Brain Res. 2001;123:77-87.
101. Joel D, Avisar A, Doljansky J. Enhancement of excessive lever-pressing after posttraining signal attenuation in rats by repeated administration of the D1 antagonist SCH 23390 or the D2 agonist quinpirole, but not the D1 agonist SKF 38393 or the D2 antagonist haloperidol. Behav Neurosci. 2001;115:1291-1300.
102. Joel D, Doljansky J. Selective alleviation of compulsive lever-pressing in rats by D(1), but not D(2), blockade: possible implications for the involvement of D(1) receptors in obsessive-compulsive disorder. Neuropsychopharmacology 2003;28:77-85.
103. Man J, Hudson AL, Ashton D, Nutt DJ. Animal models for obsessive-compulsive disorder. Curr Neuropharmacol. 2004;2:169-181.